Outlook Therapeutics, Inc. (OTLK)

Outlook Therapeutics is shifting from regulatory approval toward commercialization of LYTENAVA for wet age-related macular degeneration. Recent leadership appointments support the planned U.S. launch, while the August financing strengthened liquidity but created dilution and funding concerns. Management has projected more than $500 million in annual U.S. sales by 2030, subject to commercial execution.